ArticleBMC pediatrics2026
Plasma clusterin levels in autism spectrum disorder: bridging biomarkers to social and cognitive dysfunctions.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAutism Spectrum Disorder (ASD) is a set of complex neurodevelopmental disorders that affect social, communication, and behavioral development, as well as other associated areas such as sensory processing. Extensive research evidence suggests that clusterin (CLU) exerts essential physiological processes in the human body, including neuroprotection, neuroinflammation, cellular arrest, chemoresistance, and apoptosis, that are considered hallmarks in the pathophysiology of autism spectrum disorder (ASD). The contributing role of CLU in neurodegenerative disorders has been widely accepted. However, its role in neurodevelopmental disorders like ASD remains largely unexplored. Therefore, we aimed to investigate the potential role of plasma CLU as a biomarker for ASD and its relationship with ASD severity and social impairment.
methodsPlasma CLU level was measured in 38 children with ASD (aged 3–12 years) compared to 40 age and sex-matched healthy controls (aged 3–13 years), using enzyme-linked immunosorbent assay (ELISA). The childhood autism rating scale (CARS) and Social Responsiveness Scale (SRS) were used to assess the severity of ASD and social impairment, respectively. Spearman’s correlations (r) between CLU, CARS, SRS, and age were calculated by SPSS.
resultsOur results indicated that the plasma CLU levels in the ASD group were significantly higher [(median (IQR), 13.61 (8.25)] than in controls [11.75 (7.08)], p=0.041. Furthermore, children with severe autism and impaired social interactions exhibited a significantly higher plasma CLU level [14.08 (13.55)] compared to the mild to moderate subgroup [9.29 (4.80)], p=0.01. However, there was no significant correlation between CLU and severity scores (CARS, SRS) and age of ASD subjects (p>0.05).
conclusionThis study shows that plasma CLU levels could be implicated in the pathophysiology of ASD and may serve as a potential biomarker for ASD. Furthermore, our results suggest that CLU may be associated with the severity of social behavior impairments. However, there was no correlation between CLU and the severity of the disease. More studies with large populations are required to confirm the role of CLU in ASD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.